We are live on
!
Find out more
SL
Siren LLC Portfolio holdings
AUM
$3.61B
1-Year Est. Return
203.3%
This Fund
S&P 500
This Quarter
Est. Return
+22.99%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2B
AUM Growth
–
Cap. Flow
+$1.96B
Cap. Flow
% of AUM
97.94%
Top 10 Holdings %
Top 10 Hldgs %
41.25%
Holding
112
New
112
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$131M |
| 2 |
ONC
BeOne Medicines Ltd
ONC
|
+$101M |
| 3 |
Scholar Rock
SRRK
|
+$98.9M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$80.3M |
| 5 |
BCAX
Bicara Therapeutics
BCAX
|
+$78.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.5% |
| 2 | Technology | 2.87% |
| 3 | Communication Services | 1.83% |
| 4 | Consumer Discretionary | 0.77% |
| 5 | Real Estate | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cytokinetics
CYTK
$10.4B
| $27.8M | 1.39% |
+525,971
| New | +$29.3M |
|
27
Kura Oncology
KURA
$850M
| $26.2M | 1.31% |
+1,339,942
| New | +$27.2M |
|
28
Arcus Biosciences
RCUS
$3.64B
| $24.6M | 1.23% |
+1,612,077
| New | +$25.4M |
|
29
Denali Therapeutics
DNLI
$3.97B
| $24.3M | 1.21% |
+834,028
| New | +$20.7M |
|
30
Erasca
ERAS
$6.39B
| $24.2M | 1.21% |
+8,857,179
| New | +$24.9M |
|
31
Cullinan Oncology
CGEM
$1.14B
| $20.3M | 1.01% |
+1,211,357
| New | +$21.5M |
|
32
Tango Therapeutics
TNGX
$4.41B
| $20.1M | 1% |
+2,603,897
| New | +$24.8M |
|
33
Solid Biosciences
SLDB
$900M
| $19.2M | 0.96% |
+2,749,041
| New | +$22.3M |
|
34
Prothena Corp
PRTA
$450M
| $18.4M | 0.92% |
+1,099,840
| New | +$23.6M |
|
35
NewAmsterdam Pharma
NAMS
$3.34B
| $15.3M | 0.76% |
+920,564
| New | +$15.9M |
|
36
Biohaven
BHVN
$2.21B
| $14.2M | 0.71% |
+283,540
| New | +$11M |
|
37
Korro Bio
KRRO
$195M
| $14M | 0.7% |
+418,833
| New | +$17.6M |
|
|
APLT
38
DELISTED
Applied Therapeutics
APLT
| $13.9M | 0.69% |
+1,633,768
| New | +$9.63M |
|
39
Gossamer Bio
GOSS
$87M
| $13.1M | 0.65% |
+13,281,610
| New | +$12.8M |
|
40
Instil Bio
TIL
$50.3M
| $13M | 0.65% |
+192,433
| New | +$4.53M |
|
41
Edgewise Therapeutics
EWTX
$4.73B
| $10.8M | 0.54% |
+404,113
| New | +$8.04M |
|
42
Iovance Biotherapeutics
IOVA
$2.87B
| $10.4M | 0.52% |
+1,106,040
| New | +$10.5M |
|
43
Oric Pharmaceuticals
ORIC
$1.4B
| $10.3M | 0.52% |
+1,007,575
| New | +$9.96M |
|
44
Ionis Pharmaceuticals
IONS
$9.4B
| $10M | 0.5% |
+250,000
| New | +$11.6M |
|
45
Taysha Gene Therapies
TSHA
$1.89B
| $9.81M | 0.49% |
+4,879,875
| New | +$10.7M |
|
46
Microsoft
MSFT
$3.71T
| $9.46M | 0.47% |
+22,000
| New | +$9.4M |
|
47
Cartesian Therapeutics
RNAC
$268M
| $9.22M | 0.46% |
+572,236
| New | +$8.94M |
|
|
SLRN
48
DELISTED
ACELYRIN
SLRN
| $8.53M | 0.43% |
+1,729,665
| New | +$8.93M |
|
49
Phathom Pharmaceuticals
PHAT
$692M
| $8.33M | 0.42% |
+460,753
| New | +$6.44M |
|
50
Seer Inc
SEER
$120M
| $7.88M | 0.39% |
+4,000,000
| New | +$7.01M |
|
Similar funds
SCM
ACM
GCM
VI
BPS
VPC
WWA
OCM
Siren LLC's Q3 2024 Portfolio in Review
Q3 2024 is the first quarter with a 13F filing on record for Siren LLC, which disclosed 112 positions worth $2B. Its ten largest holdings account for 41% of the portfolio.
Its largest position is Kymera Therapeutics: 2,969,733 shares worth $141M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Technology and Communication Services.
- Siren LLC's largest Q3 2024 buy was Kymera Therapeutics: 2,969,733 shares worth $141M.
- Siren LLC's ten largest holdings make up 41% of its $2B portfolio in Q3 2024.
- Siren LLC disclosed 112 positions in Q3 2024, its first 13F filing on record.
Based on Siren LLC's 13F filing for Q3 2024, filed 13 Nov 2024.